Autoimmune Uveitis Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | Tarsier, Eli Lilly, Oculis Pharma, Eyevensys, AbbVie, Allergan, Eyevensys, ACELYRIN, Alimera

Autoimmune Uveitis Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | Tarsier, Eli Lilly, Oculis Pharma, Eyevensys, AbbVie, Allergan, Eyevensys, ACELYRIN, Alimera
Delveinsight Business Research LLP
Autoimmune Uveitis Market size in the 7MM was USD 1,261 million in 2021. Autoimmune Uveitis Market is expected to increase by 2032 at a decent CAGR. As per DelveInsight, the Autoimmune Uveitis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Autoimmune Uveitis and the launch of new therapies in the market.

DelveInsight’s “Autoimmune Uveitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Autoimmune Uveitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Autoimmune Uveitis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Autoimmune Uveitis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Autoimmune Uveitis: An Overview

Uveitis is a sight-threatening inflammation inside the eye that affects both the uveal tract and adjacent structures. Uveitis can result in temporary or permanent visual impairment and ocular problems that are not responsive to treatment since the condition involves recurrent intraocular inflammation. Vision blurriness, photophobia, eye pain, floaters (floating spots), headaches, and injected conjunctiva are all typical signs of uveitis. It is usually asymptomatic in children.

Autoimmune uveitis is an inflammatory process of uveal components due to an autoimmune reaction to self-antigens or is caused by an innate inflammatory reaction secondary to an external stimulus. Eye inflammation can be the initial presentation in many autoimmune diseases (AD), manifesting as conjunctivitis, episcleritis, or scleritis. Diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are commonly associated with these manifestations. On the other hand, anterior uveitis typically appears as the initial manifestation of autoinflammatory diseases such as ankylosing spondylitis (AS).

Autoimmune Uveitis Market Key Facts

  • Among all the 7MM, the US consistently captured the highest total Autoimmune Uveitis market size, with USD 814 million in 2021.

  • In 2021, EU4 and the UK captured an estimated USD 310 million of the total Autoimmune Uveitis market size.

  • Among the 7MM, Japan represented approximately 11% of the total Autoimmune Uveitis market size, with USD 137 million in 2021.

  • As per the Autoimmune Uveitis market size by therapies for treatment, Biologics captured the highest market size of USD 933 million in 2021.

  • The total diagnosed prevalent cases of uveitis in 2021 in the 7MM were 925,168; it is estimated to increase by 2032, at a constant CAGR.

  • In 2021, 65,000+ total diagnosed prevalent cases of autoimmune uveitis were estimated in the 7MM. These cases are anticipated to rise due to the increase in population by 2032.

  • In 2021, the US accounted for the highest diagnosed prevalent cases of Autoimmune Uveitis, which is anticipated to rise from 289,000+ cases by 2032.

  • Among the European countries, Germany had the highest diagnosed prevalent population of Autoimmune Uveitis (73,000+ cases), followed by France (65,000+ cases) and the UK (47,000+ cases) in 2021. On the other hand, Italy (35,000+ cases) had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.

  • In Japan, 113,000+ diagnosed prevalent cases of Autoimmune Uveitis were recorded in 2021, accounting for 17% of the total diagnosed prevalent population in the 7MM. 

  • The current pipeline of Autoimmune Uveitis consists of a great deal of drugs for treatment, such as TRS01, OCS-02, EYS606, and others targeting a wide range of mechanisms. Ongoing research and current trials have the potential to change the market.

Autoimmune Uveitis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Autoimmune Uveitis pipeline therapies. It also thoroughly assesses the Autoimmune Uveitis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Autoimmune Uveitis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Autoimmune Uveitis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Autoimmune Uveitis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Autoimmune Uveitis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Autoimmune Uveitis Epidemiology, Segmented as –

  • Total Diagnosed Prevalent Cases of Uveitis in the 7MM [2019–2032]

  • Etiology-specific Diagnosed Prevalent Cases of Autoimmune Uveitis in the 7MM [2019–2032]

  • Type-specific Diagnosed Prevalent Cases of Uveitis in the 7MM [2019–2032]

  • Total Diagnosed Prevalent Cases of NIU by Anatomical Location in the 7MM [2019–2032]

  • Total Diagnosed Prevalent Cases Of Autoimmune Uveitis in the 7MM [2019–2032]

Autoimmune Uveitis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Autoimmune Uveitis market or expected to be launched during the study period. The analysis covers the Autoimmune Uveitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Autoimmune Uveitis drugs based on their sale and market share.

The report also covers the Autoimmune Uveitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Autoimmune Uveitis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Autoimmune Uveitis Market Will Evolve and Grow by 2032 @

Autoimmune Uveitis Therapeutics Analysis

Patients with Autoimmune Uveitis have benefited from the approval of novel, disease-specific drugs in treating the patients. Over recent years, significant advances have been made in Autoimmune Uveitis management, and the potential is greater for affected patients to move closer to living a life that is not overshadowed by disease morbidity.

The dynamics of the Autoimmune Uveitis market are anticipated to change in the coming years owing to the expected approval of emerging therapies focused on the treatment of Autoimmune Uveitis during the forecasted period of 2023‒2032. There are presently several key players in the market including Tarsier Pharma, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., and others.

Autoimmune Uveitis Companies Actively Working in the Therapeutics Market Include

  • Tarsier Pharma

  • Eli Lilly and Company

  • Oculis Pharma

  • Eyevensys

  • Priovant Therapeutics, Inc.

  • EyePoint Pharmaceuticals

  • AbbVie Inc.

  • Allergan plc.

  • Bausch & Lomb

  • Alimera Sciences

  • Tarsier Pharma

  • EEyevensys

  • Priovant Therapeutics, Inc.


And Many Others

Emerging and Marketed Autoimmune Uveitis Therapies Covered in the Report Include:

  • YUTIQ: EyePoint Pharmaceuticals

  • HUMIRA (Adalimumab): AbbVie Inc.

  • OZURDEX: AbbVie Inc. /Allergan plc.

  • RETISERT: Bausch & Lomb

  • ILUVIEN: Alimera Sciences

  • TRS01: Tarsier Pharma

  • OCS-02: Oculis Pharma

  • EYS606: Eyevensys

  • Brepocitinib: Priovant Therapeutics, Inc.

  • Izokibep: ACELYRIN Inc.

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Autoimmune Uveitis Competitive Intelligence Analysis

4. Autoimmune Uveitis Market Overview at a Glance

5. Autoimmune Uveitis Disease Background and Overview

6. Autoimmune Uveitis Patient Journey

7. Autoimmune Uveitis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Autoimmune Uveitis Treatment Algorithm, Current Treatment, and Medical Practices

9. Autoimmune Uveitis Unmet Needs

10. Key Endpoints of Autoimmune Uveitis Treatment

11. Autoimmune Uveitis Marketed Therapies

12. Autoimmune Uveitis Emerging Drugs and Latest Therapeutic Advances

13. Autoimmune Uveitis Seven Major Market Analysis

14. Attribute Analysis

15. Autoimmune Uveitis Market Outlook (In US, EU5, and Japan)

16. Autoimmune Uveitis Companies Active in the Market

17. Autoimmune Uveitis Access and Reimbursement Overview

18. KOL Views on the Autoimmune Uveitis Market

19. Autoimmune Uveitis Market Drivers

20. Autoimmune Uveitis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Artificial Disc Market

In 2021, Global Artificial Disc Market was USD 1.59 billion and it is projected to grow at a CAGR of 11.16% from 2023 to 2028, aiming to hit USD 3.01 billion. Factors driving this growth include a rising elderly population, higher degenerative disc disorder cases, increased trauma and sports injuries, and heightened product development activities, among other factors. Some of the key companies in the Artificial Disc Market include Stryker, Zimmer Biomet, DePuy Synthes (Medical Devices Business Services, Inc.), Medtronic, Globus Medical, B. Braun Melsungen AG, Orthofix Medical Inc., NuVasive Inc., Centinel Spine®, LLC, SYNERGY SPINE SOLUTIONS INC., AxioMed LLC, Spineart, NEURO FRANCE Implants, Norm Medical Devices Co. Ltd., Ackermann Medical GmbH & Co. KG, Aditus Medical, Evospine GmbH, Prodorth Spine, SIGNUS Medizintechnik GmbH, Spine Innovations SAS, and others.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States